172 related articles for article (PubMed ID: 34711954)
1. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
Cherif C; Nguyen DT; Paris C; Le TK; Sefiane T; Carbuccia N; Finetti P; Chaffanet M; Kaoutari AE; Vernerey J; Fazli L; Gleave M; Manai M; Barthélémy P; Birnbaum D; Bertucci F; Taïeb D; Rocchi P
Oncogene; 2022 Jan; 41(1):125-137. PubMed ID: 34711954
[TBL] [Abstract][Full Text] [Related]
2. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
3. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
5. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
7. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
8. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Baylot V; Katsogiannou M; Andrieu C; Taieb D; Acunzo J; Giusiano S; Fazli L; Gleave M; Garrido C; Rocchi P
Mol Ther; 2012 Dec; 20(12):2244-56. PubMed ID: 22893039
[TBL] [Abstract][Full Text] [Related]
9. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
10. LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Han C; Yu G; Mao Y; Song S; Li L; Zhou L; Wang Z; Liu Y; Li M; Xu B
PLoS One; 2020; 15(11):e0240801. PubMed ID: 33137125
[TBL] [Abstract][Full Text] [Related]
11. Targeting the MLL complex in castration-resistant prostate cancer.
Malik R; Khan AP; Asangani IA; Cieślik M; Prensner JR; Wang X; Iyer MK; Jiang X; Borkin D; Escara-Wilke J; Stender R; Wu YM; Niknafs YS; Jing X; Qiao Y; Palanisamy N; Kunju LP; Krishnamurthy PM; Yocum AK; Mellacheruvu D; Nesvizhskii AI; Cao X; Dhanasekaran SM; Feng FY; Grembecka J; Cierpicki T; Chinnaiyan AM
Nat Med; 2015 Apr; 21(4):344-52. PubMed ID: 25822367
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Ann Oncol; 2016 Jun; 27(6):1116-1122. PubMed ID: 27022067
[TBL] [Abstract][Full Text] [Related]
13. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
14. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Nollet EA; Cardo-Vila M; Ganguly SS; Tran JD; Schulz VV; Cress A; Corey E; Miranti CK
Oncogene; 2020 Jul; 39(31):5390-5404. PubMed ID: 32565538
[TBL] [Abstract][Full Text] [Related]
16. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
17. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
18. Tpl2 induces castration resistant prostate cancer progression and metastasis.
Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
[TBL] [Abstract][Full Text] [Related]
19. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
[TBL] [Abstract][Full Text] [Related]
20. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
